Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Proteolysis targeting peptide (PROTAP) strategy for protein ubiquitination and degradation.

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Targeting UBE2C for Degradation by Bioprotacs Based on Bacterial E3 Ligase

Targeted Protein Degradation: Principles, Strategies, and Applications

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Ubiquitin‐Independent Degradation: An Emerging PROTAC Approach?

Recent advances in targeted protein degraders as potential therapeutic agents

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Discovery of a Keap1-dependent Peptide PROTAC to Knockdown Tau by Ubiquitination-Proteasome Degradation Pathway.

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Targeted protein degradation: expanding the toolbox

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

The Application Of Ubiquitin Ligases In The Protac Drug Design

Targeted protein degradation: mechanisms, strategies and application

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins